AtomVie Global Radiopharma, a radiopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced on Tuesday that it has entered into an agreement with Radiopharm Ventures (RV), a joint venture between Radiopharm Theranostics (ASX:RAD) and MD Anderson Cancer Center (MDACC).

The agreement is for the development and production of 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody. The collaboration is intended to utilise both firm's expertise to advance novel radiotherapeutic solutions in areas of high unmet medical needs.

B7-H3, an immune checkpoint molecule, is overexpressed in various tumour types and represents a highly attractive target for antibody-based cancer immunotherapy. Deregulated B7-H3 expression is connected with tumour aggressiveness and poor outcome.

This partnership integrates RAD's platform of radiotherapeutic products and AtomVie's expertise in manufacturing and distributing radiopharmaceuticals worldwide. B7-H3 is part of a broader pipeline of distinct, highly differentiated technologies developed by Radiopharm Theranostics and RV. These include peptides, small molecules and monoclonal antibodies for use in cancer, sourced from universities and institutes worldwide.